Drug Search Results
More Filters [+]

JNJ-40411813

Alternative Names: jnj-40411813, jnj40411813, jnj 40411813, ADX71149, ADX-71149, ADX 71149
Latest Update: 2024-09-30
Latest Update Note: News Article

Product Description

JNJ-40411813 is a positive allosteric modulator of mGluR2 for the treatment of seizures being developed by Addex and Johnson & Johnson. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25735992/)

Mechanisms of Action: MGLUR2/3 Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: Addex Pharma

Clinical Description

Map of Global Clinical Trials for JNJ-40411813

Countries in Clinic: Belgium, Germany, Japan, Korea, Poland, Russia, Spain, Ukraine, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Seizures

Phase 1: Epilepsy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A study to investigate JNJ-40411813 in combination with levetiracetam in epilepsy

P2

Active, not recruiting

Seizures

2024-06-10

CR108943

P2

Completed

Seizures

2024-02-08

32%

jRCT2071200090

P1

Active, not recruiting

Epilepsy

2021-05-25

Recent News Events